Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi Lawsuit – MGX

Core Viewpoint - A class action securities lawsuit has been filed against Metagenomi, Inc. due to alleged securities fraud affecting investors who purchased shares during its initial public offering in February 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who bought shares based on Metagenomi's registration statement during its IPO held from February 9 to 13, 2024 [2]. - The complaint highlights that Metagenomi presented itself as a "genetic medicines company" with a significant partnership with Moderna, which was a key aspect of its business model [3]. - Metagenomi completed its IPO by selling 6.25 million shares at $15 per share, but the partnership with Moderna was terminated less than three months later on May 1, 2024, leading to a decline in stock price from $7.04 to $6.17 per share [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until November 25, 2024, to request to be appointed as lead plaintiff in the lawsuit [4]. - Participation in the lawsuit does not require any out-of-pocket costs or fees for class members [4]. Group 3: Law Firm Background - Levi & Korsinsky has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [5].